Skip to content

Alumis Inc. ALMS Research And Development Prepaid Expenses

Research And Development Prepaid Expenses at other companies

Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$4.59M-52.5%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$6.81M+56.1%
Zymeworks logo
ZymeworksZYME
$7.26M+19.6%
Erasca, Inc. logo
Erasca, Inc.ERAS
$150M
Polaryx Therapeutics, Inc.
 logo
Polaryx Therapeutics, Inc. PLYX
$86K
Johnson & Johnson logo
Johnson & JohnsonJNJ
$96.25M-78.4%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept alms:ResearchAndDevelopmentPrepaidExpenses.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s research and development prepaid expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s research and development prepaid expenses?
Alumis Inc. (ALMS) reported research and development prepaid expenses of $3.35M in Q1 2026.
How has Alumis Inc.'s research and development prepaid expenses changed year-over-year?
Alumis Inc.'s research and development prepaid expenses decreased by 74.0% year-over-year, from $12.86M to $3.35M.
What is the long-term trend for Alumis Inc.'s research and development prepaid expenses?
Over 2 years (2023 to 2025), Alumis Inc.'s research and development prepaid expenses has grown at a 4.6% compound annual growth rate (CAGR), from $2.66M to $2.91M.
What does research and development prepaid expenses mean?
This represents payments made in advance to vendors or partners for research and development services or materials that have not yet been received or utilized. It reflects the company's commitment to future clinical trials and drug discovery activities. Monitoring this balance helps investors understand the pipeline of upcoming R&D activities and the timing of associated cash outflows.